Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacodynamic Equivalence Study of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular Fixed Dose Combination Pill AAR as Compared to Monotherapy With the Reference Products Altace® 10 mg and Lipitor® 40 mg

NCT02791958 is registered in ClinicalTrials.gov with Ferrer Internacional S.A. as lead sponsor.

NCT NCT02791958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02791958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacodynamic Equivalence Study of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular Fixed Dose Combination Pill AAR as Compared to Monotherapy With the Reference Products Altace® 10 mg and Lipitor® 40 mg
Lead sponsor
Ferrer Internacional S.A.
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2016
Completion date
October 31, 2017
Enrollment
528 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension